PSMB8 and proteosome-associated autoinflammatory syndrome: This drug was used recently in a patient with a CANDLE syndrome (PRAAS) caused by a compound heterozygous mutation in the PSMB8 gene with significant clinical improvement, at a maintenance dosage of 8mg/day (138).